** Shares of drug developer Spruce Biosciences SPRB.O rise 27% to $74 premarket

**  Co says its therapy targets Sanfilippo Syndrome Type B, a rare genetic disorder that causes progressive brain damage and loss of motor skills in children

** Co says FDA confirmed its existing clinical data could support an accelerated review of its experimental enzyme‑replacement therapy

**  Co says the treatment aims to replace a missing enzyme to slow or halt disease progression

**  Co says the drug has been tested in 22 patients over six years with a favorable safety profile

** SPRB says it expects to file its application in Q4 2026 after completing FDA manufacturing requirements

** Shares up ~177% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))